Results 21 to 30 of about 12,163 (174)

Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation

Cardiology and Therapy, 2023
Introduction Treatment adherence and persistence impact the effectiveness of edoxaban for the prevention of thromboembolism in patients with atrial fibrillation (AF).
Giuseppe Patti, Rosa Wang, Xiaocong Li Marston, Yu-Chen Yeh, Lisa Zimmermann, Xin Ye, Xin Gao, Bernd Brüggenjürgen   +7 more
doaj   +1 more source

Hip fractures risks in edoxaban versus warfarin users: A propensity score-matched population-based cohort study with competing risk analyses

, 2021
The three direct oral anticoagulants (DOAC), rivaroxaban, apixaban and dabigatran have been associated with lower risks of fractures compared to warfarin. However, no large scale studies have explored the associations with the newest DOAC, edoxaban, with
Hou In Chou, Oscar, Liu, Xuejin, Tai Loy Lee, Teddy, Liu, Tong, Iltaf Satti, Danish, Lee, Sharen, Zhou, Jiandong, Tse, Gary, Roever, Leonardo, Ka Chung Wai, Abraham, Zhang, Qingpeng, Chang, Carlin, Tak Wong, Wing   +12 more
core   +1 more source

Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis

Medicines, 2023
Background: Edoxaban is a novel oral anticoagulant which may decrease the risk of stroke and systemic embolism in patients suffering from atrial fibrillation (AF).
Yapeng Wang, Li Li, Zhanlan Wei, Shan Lu, Wenxue Liu, Janghui Zhang, Junbo Feng, Dongjin Wang   +7 more
doaj   +1 more source

Study of weight variation and dissolution of Edoxaban split tablets in pharmacy practice [PDF]

Pharmaceutical Sciences Asia, 2022
Edoxaban is available in 60 mg, 30 mg, and 15 mg unscored film-coated tablets. Tablet splitting may be an option to reduce medication costs and reduce the country’s budget.
Mantiwee Nimworapan, Sinwisuth Sutheechai, Wanwarang Wongcharoen, Arintaya Phrommintikul, Suntara Eakanunkul   +4 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux   +3 more
core   +1 more source

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator [PDF]

, 2023
A universal calibrator for the determination of all anti-Xa inhibitors would support laboratory processes. We aimed to test the clinical performance of an anti-Xa assay utilizing a universal edoxaban calibrator to determine clinically relevant ...
Gerber, B., Cédric Bovet, Burger, A., Mendez, Adriana, Mendez, A., Walter A. Wuillemin, Adriana Mendez, Wuillemin, W.A., Studt, J.D., Binder, Nikolaus B, Thomas Sauter, Michael Nagler, Studt, Jan-Dirk, Alberio, Lorenzo, Alberio, L., Schmidt, Adrian, Lorenzo Alberio, Annika Burger, Bovet, C., Adrian Schmidt, Nikolaus Binder, Schmidt, A., Nagler, M., Pierre Fontana, Graf, Lukas, Lukas Graf, Burger, Annika, Bernhard Gerber, Gerber, Bernhard, Sauter, Thomas C, Thomas C. Sauter, Graf, L., Binder, N.B., Nikolaus B. Binder, Jan-Dirk Studt, Fontana, P., Nagler, Michael, Sauter, T.C., Fontana, Pierre, Bovet, Cédric, Wuillemin, Walter A, Walter Wuillemin   +41 more
core   +2 more sources

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)

Thrombosis Journal, 2023
Background Gynecological cancer is one of the highest risk factors for cancer-associated thrombosis (CAT). Although low-molecular-weight heparin (LMWH) is recommended as an anticoagulant for treating CAT, recent studies have shown that direct oral ...
Tadashi Oride, Kenjiro Sawada, Aasa Shimizu, Yasuto Kinose, Tsuyoshi Takiuchi, Michiko Kodama, Kae Hashimoto, Eiji Kobayashi, Eiji Nakatani, Tadashi Kimura   +9 more
doaj   +1 more source

Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial

, 2023
Objective: Early warfarin anticoagulation is recommended in patients undergoing surgical bioprosthetic valve implantation or valve repair. It is unclear whether non-vitamin K antagonist oral anticoagulants can be a full alternative to warfarin.
이삭, 서지원, 이찬주, 김영진, 홍그루, 심지영, 서영주, 이승현, 하종원, 신동호   +9 more
core   +1 more source

Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)

Thrombosis Journal, 2019
Background This study involved a sensory evaluation of edoxaban orally disintegrating (OD) tablets in patients with nonvalvular atrial fibrillation who had been receiving the existing edoxaban film-coated tablets before the study.
Takeshi Yamashita, Joji Hagii, Yoshiyuki Morishima, Takaaki Akasaka, Takuyuki Matsumoto, Tetsuya Kimura   +5 more
doaj   +1 more source

Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. [PDF]

PLoS ONE, 2014
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with non-valvular atrial fibrillation (AF). We conducted an imputed-placebo analysis with estimates of the proportion of warfarin effect preserved by each non
Paolo Verdecchia, Fabio Angeli, Gregory Y H Lip, Gianpaolo Reboldi   +3 more
doaj   +1 more source